<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref1">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Abarca</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Jung</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Fernández</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Harris</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Connor</surname>
    <given-names>E. M.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2009</year>). 
  <article-title>Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children</article-title>. 
  <source>Pediatr. Infect. Dis. J.</source>
  <volume>28</volume>, 
  <fpage>267</fpage>–
  <lpage>272</lpage>. 
  <pub-id pub-id-type="doi">10.1097/INF.0b013e31818ffd03</pub-id>, PMID: 
  <?supplied-pmid 19258920?>
  <pub-id pub-id-type="pmid">19258920</pub-id>
 </mixed-citation>
</ref>
